pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›XTAMPZA ER
drug · small molecule
save

XTAMPZA ER

updated 3mo ago
/ OK-see-KOH-dohn /
by $COLL COLLEGIUM PHARMACEUTICAL, INC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval1,218 co-mentions · 596 sources
  • drugHYDROCODONE BITARTRATE AND ACETAMINOPHEN678 co-mentions · 340 sources
  • drugoxycodone ER638 co-mentions · 599 sources
  • tagSmall Molecule609 co-mentions · 596 sources
  • drugOXYCODONE HYDROCHLORIDE333 co-mentions · 260 sources
  • drugOXYCODONE AND ACETAMINOPHEN326 co-mentions · 326 sources
  • drugOXYCONTIN295 co-mentions · 260 sources
  • drugROXICODONE272 co-mentions · 260 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 30 investigational indications.

targets

Mu-type opioid receptor

all catalysts(0)

nothing on the calendar yet

Trials studying XTAMPZA ER

  • —Anesthetics and Analgesics in Childrenrecruitingn=500
  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • N/AIntercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatumcompletedn=50
  • phase3A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomycompletedn=240
  • phase1A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjectscompletedn=20
  • phase1Buprenorphine-Fentanyl Interaction Studycompletedn=22
  • —Impact of Opioid Avoidance Protocol for ACL Reconstructioncompletedn=32
  • phase3Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extractioncompletedn=288
more trials →

News(2)

  • STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
    Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
    stat · 16d ago
  • Super-potent synthetic opioids called nitazenes are spreading across the U.S.
    Overdose deaths confirmed to involve nitazenes have risen sharply in the U.S., from 27 in 2020 to 409 in 2024, according to the CDC
    stat · 1mo ago
brand
XTAMPZA ER
trade names
Proladone, Xtampza er
generic
OXYCODONE
MOA
12.1 Mechanism of Action Oxycodone is a full opioid agonist and is relatively selective for the mu receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. In addition, when oxycodone binds to mu-opioid receptors, it results in positive subjective effects, such as drug liking, euphoria, and high.
indication
1 INDICATIONS AND USAGE XTAMPZA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. XTAMPZA ER is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death,which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment optionsare ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) XTAMPZA ER is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ], reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. XTAMPZA ER is not indicated as an as-needed (prn) analgesic.
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 15m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?